ID
AKBA icon

Integral Derivatives’s Akebia Therapeutics AKBA Stock Holding History

Integral Derivatives’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13,400
Closed -$114K – 984
2016
Q2 		$100K Buy
+13,400
New +$117K ﹤0.01% 900

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Integral Derivatives's AKBA Position: Q3 2016 in Review

Integral Derivatives sold out of Akebia Therapeutics (AKBA) in Q3 2016, closing a stake of 13,400 shares — an estimated $114K sold.

Integral Derivatives first reported a position in AKBA in Q2 2016 and held it in 1 quarter. The position peaked at $100K in Q2 2016. 86 funds tracked by Wall St. Rank hold AKBA as of Q3 2016.

  • Integral Derivatives reported no remaining Akebia Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Integral Derivatives sold 13,400 Akebia Therapeutics shares in Q3 2016, an estimated $114K.
  • Integral Derivatives first reported a position in Akebia Therapeutics in Q2 2016 and held it in 1 quarter.
  • Integral Derivatives's Akebia Therapeutics position peaked at $100K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2016.

Based on Integral Derivatives's 13F filing for Q3 2016, filed 14 Nov 2016.